Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rash of Generic Price Hikes Pushes UK Health Dept Into Action

Executive Summary

Huge hikes in the prices of some generic medicines in the past year have forced the UK health authorities to offer many more “concessionary prices” to pharmacists to ensure continuity of supply and to seek alternative sources of some products. Legislation is due to take effect shortly that will give the government more powers to control generic prices.

You may also be interested in...



Court Ruling On Pfizer Price Hikes Could Delay Other Investigations, Warns UK Competition Authority

Ongoing Investigations into drug price increases could be at risk following a tribunal ruling in the UK phenytoin sodium case, according to the Competition and Markets Authority, which is considering an appeal against the judgment.

ABPI Welcomes Amended Legislation On Curbing Excessive Unbranded Drug Prices

Newly passed UK legislation gives the government powers to curb pricing of unbranded generics when market forces fail. The Association of the British Pharmaceutical Industry has welcomed amendments to draft legislation that have addressed its concerns over onerous requirements.

EU Bodies Back Mix-And-Match Approach For COVID-19 Boosters

New advice on the use of "mix-and-match" primary and booster vaccine regimens has been published by the EMA and the ECDC, while a new CEPI-supported clinical trial will test heterologous booster combinations involving Medigen’s COVID-19 vaccine and other jabs.

Topics

UsernamePublicRestriction

Register

PS123270

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel